These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52. Pharmacokinetics and distribution of recombinant secretory leukocyte proteinase inhibitor in rats. Gast A; Anderson W; Probst A; Nick H; Thompson RC; Eisenberg SP; Schnebli H Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):889-94. PubMed ID: 2327652 [TBL] [Abstract][Full Text] [Related]
53. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. Pillay K; Coutsoudis A; Agadzi-Naqvi AK; Kuhn L; Coovadia HM; Janoff EN J Infect Dis; 2001 Feb; 183(4):653-6. PubMed ID: 11170993 [TBL] [Abstract][Full Text] [Related]
54. Selective oxidation of methionyl residues in the human recombinant secretory leukocyte proteinase inhibitor. Effect on the inhibitor binding properties. Tomova S; Cutruzzolà F; Barra D; Amiconi G; Ascenzi P; Djinović Carugo K; Menegatti E; Sarti P; Schnebli HP; Bolognesi M J Mol Recognit; 1994 Mar; 7(1):31-7. PubMed ID: 7986566 [TBL] [Abstract][Full Text] [Related]
55. Effect of menstrual status on antibacterial activity and secretory leukocyte protease inhibitor production by human uterine epithelial cells in culture. Fahey JV; Wira CR J Infect Dis; 2002 Jun; 185(11):1606-13. PubMed ID: 12023766 [TBL] [Abstract][Full Text] [Related]
56. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Yang J; Zhu J; Sun D; Ding A Biochim Biophys Acta; 2005 Sep; 1745(3):310-7. PubMed ID: 16112212 [TBL] [Abstract][Full Text] [Related]
57. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. Sallenave JM; Donnelly SC; Grant IS; Robertson C; Gauldie J; Haslett C Eur Respir J; 1999 May; 13(5):1029-36. PubMed ID: 10414400 [TBL] [Abstract][Full Text] [Related]
58. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Shugars DC; Sauls DL; Weinberg JB Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661 [TBL] [Abstract][Full Text] [Related]
59. A novel cysteine proteinase (CP65) of Trichomonas vaginalis involved in cytotoxicity. Alvarez-Sánchez ME; Avila-González L; Becerril-García C; Fattel-Facenda LV; Ortega-López J; Arroyo R Microb Pathog; 2000 Apr; 28(4):193-202. PubMed ID: 10764610 [TBL] [Abstract][Full Text] [Related]
60. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. Zhang Y; DeWitt DL; McNeely TB; Wahl SM; Wahl LM J Clin Invest; 1997 Mar; 99(5):894-900. PubMed ID: 9062347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]